The Moderna vaccine has been authorized for adults aged 50-64.
The Food and Drug Administration approved the Moderna mRNA-based flu vaccine this week, according to the pharmaceutical company. The inoculation is based on the same messenger RNA platform as the COVID-19 vaccine and received approval for adults aged 50-64.
The shot received accelerated approval for adults 65 and above, so the vaccine may be given while the company completes a study on its effectiveness for seniors.
The Centers for Disease Control and Prevention released data showing that, during the 2024-2025 flu season, 57 percent of flu-related hospitalizations and 71 percent of deaths occurred among those over 65 years of age.
Health and Human Services Secretary, who prioritized vaccine safety, canceled 22 federal mRNA vaccine development projects last year, stating that the “technology poses more risks than benefits for these respiratory viruses.”
The FDA originally refused to review Moderna’s vaccine application based on concerns about the design of the clinical trial. The federal agency later agreed to advance the review after the pharmaceutical company disputed the initial decision.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is expected to meet in the near future to determine whether or not to recommend the newly approve vaccine.
As the Lord Leads, Pray with Us…
- For discernment for Secretary Kennedy as he heads the Department of Health and Human Services.
- For members of the immunization advisory committee as they consider recommending the new mRNA vaccine.
- For FDA Acting Commissioner Diamantas as he oversees the review of new drugs, therapies, and vaccines for safety.
- For medical professionals to be prudent as they recommend inoculations for the flu and other diseases.
Sources: Fox News, UPI News
